 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...345678910111213...1516» |
- || Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Clinical, PK/PD data, Journal: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV. (Pubmed Central) - Jan 4, 2022
The monthly regimen consists of an oral lead-in period (rilpivirine 25 mg tablets once daily for 4 weeks), followed by an initiation injection of 900 mg rilpivirine LA, then 600 mg rilpivirine LA continuation injections monthly. The absence of a clinically relevant effect of covariates on rilpivirine pharmacokinetics suggests that rilpivirine LA dose adjustments for specific subgroups are not warranted.
- || Edurant (rilpivirine) / J&J
Review, Journal: Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention. (Pubmed Central) - Jan 4, 2022
Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.
- || Clinical, Journal: Possible Herb-Drug Interaction Risk of Some Nutritional and Beauty Supplements on Antiretroviral Therapy in HIV Patients. (Pubmed Central) - Jan 1, 2022
Of the five drugs, rilpivirine and dolutegravir metabolism was increased by up to 2-folds over the no supplement control by some of the supplements. Our findings indicate that concomitant consumption of these products with anti-HIV drugs may compromise the efficacy of antivirals therapy due to supplement-induced metabolism via induction of CYP3A4 activity.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. (Pubmed Central) - Dec 30, 2021
Our findings indicate that concomitant consumption of these products with anti-HIV drugs may compromise the efficacy of antivirals therapy due to supplement-induced metabolism via induction of CYP3A4 activity. In ART-naïve patients with low viral loads and high CD4 counts, the risk of treatment failure was lower in those who started RPV-based vs. INSTIs-based regimens other than DTG-based ones.
- | Journal: Determination of antiretroviral drugs for buyers' club in Switzerland using capillary electrophoresis methods. (Pubmed Central) - Dec 25, 2021
The developed methods were successfully applied to determine the active pharmaceutical ingredients of commercial formulations and unapproved generics. The quality control of unapproved generics by capillary electrophoresis is an attractive approach due to its good standard of quality, low cost, ecofriendliness, and ease of implementation.
- | Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
Journal: Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance. (Pubmed Central) - Dec 18, 2021
Among NRTI-SDRMs, tenofovir-associated mutations increased in prevalence while thymidine analog mutations decreased in prevalence...Among candidate NNRTI-SDRMs, six that increased in prevalence were associated with rilpivirine (E138K/Q, V179L, H221Y) or doravirine (F227C/L) resistance...We describe trends in the prevalence of nonpolymorphic HIV-1 DRMs in ART-experienced persons. These data should be considered in decisions regarding SDRM list updates and TDR monitoring.
- | Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. (Pubmed Central) - Dec 16, 2021
Most importantly, the hERG inhibition profile of 20a (IC = 19.84 μM) was a remarkable improvement. Overall, 20a possesses huge potential to serve as a promising drug candidate due to its excellent potency, low toxicity, and favorable drug-like properties.
- || Pifeltro (doravirine) / Merck (MSD)
Clinical, Journal, Real-world evidence: Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates. (Pubmed Central) - Dec 16, 2021
Overall, 20a possesses huge potential to serve as a promising drug candidate due to its excellent potency, low toxicity, and favorable drug-like properties. These results support the favorable resistance profile of doravirine, and are of particular importance given the challenge posed by both acquired and transmitted resistance.
- | Journal: Changes in BMI associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. (Pubmed Central) - Nov 17, 2021
Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens which were consistently associated with smaller BMI increases than DTG.
- || Edurant (rilpivirine) / J&J
Clinical, Retrospective data, Journal: Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS). (Pubmed Central) - Nov 16, 2021
BMI gains did not differ by regimens, except for bDRV regimens which were consistently associated with smaller BMI increases than DTG. ABC/3TC + RPV is a safe and effective switch option for maintenance therapy in virologically suppressed HIV-1 individuals with in Singapore.
- || Edurant (rilpivirine) / J&J, Vemlidy (tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Clinical, Journal: Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. (Pubmed Central) - Oct 31, 2021
Baseline ART was a predictor of post-switch weight gain: participants switching off EFV and TDF had the greatest weight gain. The biological mechanisms underlying the differential effects of switching ART agents on weight and associated clinical implications require further study.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues. (Pubmed Central) - Oct 30, 2021
The biological mechanisms underlying the differential effects of switching ART agents on weight and associated clinical implications require further study. Treatment with NNRTI plus 2 NRTI combinations is associated with a higher LS decline than other ART combinations in HIV/HCV-coinfected patients receiving DAA-based therapy.
- | Preclinical, Journal: Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice. (Pubmed Central) - Oct 30, 2021
For example, HIV persists in lymphoid tissues despite long-term oral ARV therapy, and low ARV concentrations have been found in lymphoid tissues. The improved ARV lymphatic tissue bioavailability with intramuscular and subcutaneous administration allows future studies to investigate these routes of drug administration as a therapeutic manoeuvre to limit viral persistence and eliminate viral sanctuaries in the lymphatic tissues, which is a prerequisite for eradication of HIV.
- || Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Review, Journal: NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. (Pubmed Central) - Oct 28, 2021
Indeed, there is preclinical evidence of rilpivirine being hepatoprotective in different models of liver injury, independently of the presence of HIV. The present study aims to review the mechanisms by which currently available anti-HIV drugs belonging to the NNRTI family may participate in the development of liver disease.
- | Journal: Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals. (Pubmed Central) - Oct 27, 2021
With increasing use of agents that inhibit tubular creatinine secretion, artificially low eGFR values could lead to erroneous conclusions in studies of HIV treatment and kidney outcomes measured with creatinine-based eGFR equations. Sensitivity analyses assessing the potential magnitude of bias arising from creatinine secretion inhibition should be performed.
- || Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Clinical, Journal, HEOR: Cost-Effectiveness of Juluca (dolutegravir/rilpivirine) for Human Immunodeficiency Virus (HIV-1) Infection Treatment in Virologically Suppressed Adults in Taiwan. (Pubmed Central) - Oct 20, 2021
Sensitivity analyses assessing the potential magnitude of bias arising from creatinine secretion inhibition should be performed. DTG/RPV is cost-saving compared to RPV/FTC/TDF, DTG/ABC/3TC, and EVG/c/FTC/TAF, and provides comparable efficacy with reduced cumulative drug exposure.
- | Edurant (rilpivirine) / J&J
Journal: Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity. (Pubmed Central) - Oct 16, 2021
They displayed up to single-digit nanomolar activity against wild-type (WT) and rilpivirine-associated resistant mutant E138K viruses, as well as potent inhibitory ability toward the RT enzyme...The structure-activity relationships (SARs) of the newly obtained DAPYs were also investigated. Molecular docking analysis elucidated the biological activity and offered a structural insight for follow-up research.
- | pregabalin / Generic mfg.
Preclinical, Journal: Development of a novel in vitro assay to screen for neuroprotective drugs against iatrogenic neurite shortening. (Pubmed Central) - Oct 14, 2021
Additionally, two hits originated from a previous primary screening aimed to detect inhibitors of hyperexcitability to inflammatory mediators in DRG neurons (nitrendipine and felodipine) also prevented neurite shortening in our model. In summary, in this work we developed a novel secondary assay for identifying hits with neuroprotective effect against iatrogenic neurite shortening, consistent with the anti-hyperexcitability action previously tested: highlighting nitrendipine and felodipine against iatrogenic damage in DRG neurons.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Virological failure and antiretroviral resistance among HIV-infected children after five years follow-up in the ANRS 12225-PEDIACAM cohort in Cameroon. (Pubmed Central) - Oct 14, 2021
In summary, in this work we developed a novel secondary assay for identifying hits with neuroprotective effect against iatrogenic neurite shortening, consistent with the anti-hyperexcitability action previously tested: highlighting nitrendipine and felodipine against iatrogenic damage in DRG neurons. These results show high resistance to NNRTI and emphasize the need of VL and resistance tests for optimal follow-up of HIV-infected people especially children.
- | Edurant (rilpivirine) / J&J
Journal: Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. (Pubmed Central) - Oct 14, 2021
As a result of our in silico molecular docking study, we suggest that rilpivirine is a compound that could act as a powerful inhibitor against SARS-CoV-2 targets. Although in vitro and in vivo experiments are needed to verify this prediction we believe that this antiviral drug may be used in preclinical trials to fight against SARS coronavirus.
- | Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs. (Pubmed Central) - Oct 8, 2021
(3) Excellent oral bioavailability was also revealed (F = 126%, rats) in 12g. Collectively, these novel heteroaromatic-biphenyl-DAPYs represent promising drug candidates for HIV clinical therapy.
- bictegravir (GS-9883) / Gilead
[VIRTUAL] Evaluating Weight Gain in Treatment-naïve, HIV-infected Patients Started on Antiretroviral Therapy () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1801;
The non-INSTI-based regimens were darunavir (DRV) or rilpivirine (RPV)-based...Of the patients initiated on INSTI-based regimens, 73.5% were on elvitegravir (EVG),16.7% on dolutegravir, 8.8% on bictegravir, and 0.98% on raltegravir... When comparing INSTI-based to DRV or RPV-based regimens, there was no significant increase in average weight at 6 and 18 months.
- [VIRTUAL] In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1796;
These INSTI-based regimens had high in vitro forgiveness and resistance barriers with concentrations simulating high adherence. When multiple missed doses were simulated in vitro , BIC+FTC+TAF had the highest forgiveness and barrier to resistance.
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Observational data, Retrospective data, Journal, Real-world evidence: Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. (Pubmed Central) - Oct 3, 2021
Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1-2) and led to 8 discontinuations.In this real-world cohort, switching to B/F/TAF was associated with maintenance of virologic control, and avoidance of DDIs in a large proportion of patients. These data support use of B/F/TAF as a treatment option in older PLWH.
- | Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
New P3 trial: A pilot study to evaluate the use of rilpivirine plus darunavir / cobicistat as substitute agents in virologic suppressed patients Studio pilota per valutare l'uso di rilpivirina pi (EUDRACT) - Sep 30, 2021
P3, N=160, Ongoing, Sponsor: AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Clinical, Journal: Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. (Pubmed Central) - Sep 25, 2021
P1b, P2b
Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.Clinical Trials Registration. NCT02120352.
- | Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
Journal: Structure-Based Non-Nucleoside Inhibitor Design: Developing Inhibitors that Are Effective Against Resistant Mutants. (Pubmed Central) - Sep 25, 2021
The best of the new compounds, 12, was a more potent inhibitor of the NNRTI-resistant mutants we tested than either doravirine or efavirenz but was inferior to RPV. We describe the limitations on the modifications that can be appended to the "upper right side" of the RPV core and the effects of substituting other cores for the central pyrimidine core of RPV and make suggestions about how this information can be used in NNRTI design.
- || midazolam hydrochloride / Generic mfg.
PK/PD data, Journal: Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. (Pubmed Central) - Sep 22, 2021
Quantified changes in drug dosing are most relevant during the third trimester, especially for drugs that are mainly eliminated by CYP1A2, CYP2D6 and CYP3A4 enzymes. The provided functions describing the continuous changes to the activity of these enzymes during pregnancy are important when modelling long term pharmacokinetic studies where longitudinal modelling or time-varying covariates are used.
- || Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion date: LATTE-2: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (clinicaltrials.gov) - Sep 20, 2021
P2b, N=310, Active, not recruiting, Sponsor: ViiV Healthcare
The provided functions describing the continuous changes to the activity of these enzymes during pregnancy are important when modelling long term pharmacokinetic studies where longitudinal modelling or time-varying covariates are used. Trial completion date: Feb 2022 --> Jun 2022
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Concordance of genotypic resistance interpretation algorithms in HIV-1 infected patients: An exploratory analysis in Greece. (Pubmed Central) - Sep 19, 2021
Our exploratory analysis provided evidence of significant inter-algorithm discordances, especially for PIs and NNRTIs highlighting the importance of matching the results of different algorithms to achieve optimized risk stratification. Ongoing research could assist clinical physicians in interpreting complex genotypic resistance patterns.
- Edurant (rilpivirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_649;
This fact will require an important effort to diagnose and treat DM2 early. Some antiretroviral therapy drugs could play a differential role in the development of DM2, RPV being a potentially beneficial drug.
- Comorbidities and antiretroviral utilization among people living with HIV in the United States (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_644;
A consistent ART utilization pattern was observed across comorbidity subpopulations of PLWH. Given the potential for drug-condition interactions with ART, an individualized approach to care based on clinical characteristics could minimize the risk of adverse events and exacerbation of pre-existing conditions.
- Edurant (rilpivirine) / J&J
Evolution of severe obesity and associated co-morbidities in HIV-positive patients with and without bariatric surgery: a case-control study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_638;
Given the potential for drug-condition interactions with ART, an individualized approach to care based on clinical characteristics could minimize the risk of adverse events and exacerbation of pre-existing conditions. Bariatric surgery among PLWH is safe and effective both on severe obesity and related comorbidities.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Patients’ experiences and opinions after de-simplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_563;
After STR de-simplification, most patients had a fair knowledge about generic ARVs, and they agreed to de-simplify their STR in order to decrease the costs for the healthcare system. Although almost a third of the respondents were not happy to take two pills a day, only a minority reported a worse quality of life, difficulty swallowing, or worse adherence after de-simplification.
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Impact of switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi on cardiovascular risk and lipid profile in a monocentric cohort of people living with HIV (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_562;
PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch. The majority of our patients switched from a TDF-based regimen, which is known to have an impact on lipids and weight gain.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: real-world data from the German JUNGLE cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_541;
Overall, 11% of individuals discontinued DTG/RPV due to ADRs, with only 1% in the 2nd year. This was consistent with a statistically significant improved treatment satisfaction score in patients remaining on DTG/RPV for two years.
- In vitro forgiveness of oral and long-acting INSTI-containing regimens at drug concentrations simulating variable adherence (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_526;
When simulating multiple missed doses of daily drug, all oral regimens had some VB and developed resistance; however, BIC+FTC+TAF had the highest forgiveness and barrier to resistance. Further studies with CAB+RPV are needed to understand forgiveness at the PK tail of this long-acting regimen.
- Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
The Investigation of E138 codon changes and cluster analysis in naive HIV-infected patients, Istanbul Turkey (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_523;
The diversity differences between E138 mutant and non-mutated strains can be explained by local transmission networks and clusters. That is why proxy populations should be carefully monitored to assure efficacy of treatment especially with NNRTIs.
- Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Subtype distribution and drug resistance mutations in naïve HIV-infected people, Istanbul, Turkey (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_520;
While this shows the changing subtype rates for our region, it is important in terms of the possibility of pointing to local transmission networks. Although antiretroviral resistance rates are similar to previous years, the E138 mutation that may lead to decreased resistance in second generation NNRTIs is remarkable and should be considered before starting treatment with these drugs.
- Edurant (rilpivirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_182;
This fact will require an important effort to diagnose and treat DM2 early. Some antiretroviral therapy drugs could play a differential role in the development of DM2, RPV being a potentially beneficial drug.
- Comorbidities and antiretroviral utilization among people living with HIV in the United States (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_177;
A consistent ART utilization pattern was observed across comorbidity subpopulations of PLWH. Given the potential for drug-condition interactions with ART, an individualized approach to care based on clinical characteristics could minimize the risk of adverse events and exacerbation of pre-existing conditions.
- Edurant (rilpivirine) / J&J
Evolution of severe obesity and associated co-morbidities in HIV-positive patients with and without bariatric surgery: a case-control study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_171;
Given the potential for drug-condition interactions with ART, an individualized approach to care based on clinical characteristics could minimize the risk of adverse events and exacerbation of pre-existing conditions. Bariatric surgery among PLWH is safe and effective both on severe obesity and related comorbidities.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Patients’ experiences and opinions after de-simplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_96;
After STR de-simplification, most patients had a fair knowledge about generic ARVs, and they agreed to de-simplify their STR in order to decrease the costs for the healthcare system. Although almost a third of the respondents were not happy to take two pills a day, only a minority reported a worse quality of life, difficulty swallowing, or worse adherence after de-simplification.
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Impact of switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi on cardiovascular risk and lipid profile in a monocentric cohort of people living with HIV (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_95;
PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch. The majority of our patients switched from a TDF-based regimen, which is known to have an impact on lipids and weight gain.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: real-world data from the German JUNGLE cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_74;
Overall, 11% of individuals discontinued DTG/RPV due to ADRs, with only 1% in the 2nd year. This was consistent with a statistically significant improved treatment satisfaction score in patients remaining on DTG/RPV for two years.
- In vitro forgiveness of oral and long-acting INSTI-containing regimens at drug concentrations simulating variable adherence (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_59;
When simulating multiple missed doses of daily drug, all oral regimens had some VB and developed resistance; however, BIC+FTC+TAF had the highest forgiveness and barrier to resistance. Further studies with CAB+RPV are needed to understand forgiveness at the PK tail of this long-acting regimen.
- Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
The Investigation of E138 codon changes and cluster analysis in naive HIV-infected patients, Istanbul Turkey (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_56;
The diversity differences between E138 mutant and non-mutated strains can be explained by local transmission networks and clusters. That is why proxy populations should be carefully monitored to assure efficacy of treatment especially with NNRTIs.
- Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Subtype distribution and drug resistance mutations in naïve HIV-infected people, Istanbul, Turkey (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_53;
While this shows the changing subtype rates for our region, it is important in terms of the possibility of pointing to local transmission networks. Although antiretroviral resistance rates are similar to previous years, the E138 mutation that may lead to decreased resistance in second generation NNRTIs is remarkable and should be considered before starting treatment with these drugs.
- || zidovudine / Generic mfg.
Clinical, Journal: High drug resistance levels could compromise the control of HIV infection in paediatric and adolescent population in Kinshasa, the Democratic Republic of Congo. (Pubmed Central) - Sep 17, 2021
The high DRM prevalence observed among HIV-infected children and adolescents in Kinshasa could compromise the 95-95-95-UNAIDS targets in the DRC. It also reinforces the need for routine resistance monitoring for optimal rescue therapy election in this vulnerable population to control the spread of resistant HIV in the country.
- ||| Edurant (rilpivirine) / J&J
Rilpivirine in HIV pregnant person. Do you check trough levels during 2nd/3rd trimester? Do BID dosing? Just monitor VL closely? @MonicaGandhi9 @Armstrws @PaulSaxMD @JColasantiMD (Twitter) - Sep 16, 2021